Dr. Diego Ruiz Dasilva reviews real-world data showing the safety and efficacy of combining topical ruxolitinib with systemic therapies in atopic dermatitis care.
Topics Covered:
- Combination use of ruxolitinib 1.5% cream and systemic therapies
- Real-world safety outcomes from a multicenter analysis
- Improvements in IGA, BSA, and itch scores
- Insights from RAD 2025 poster presentation
Explore Related Resources:
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Subgroup
Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream